NEU neuren pharmaceuticals limited

0.27%

$14.57

Pipeline-in-a-drug, page-2

First 2 Last

Share
Profile

Follow
Tangentland

5,949 Posts.

397

31/05/24

19:47

Post #: 74111488
Share
Originally posted by hottod: ↑

It won’t have escaped most here that, following successful Phase 2 results in the second indication of Pitt Hopkins, NNZ-2591 is being promoted by Neuren as a validated multi-indication platform.

NNZ-2591 could alternatively be described as a “pipeline-in-a-drug”. “Pipeline-in-a-drug” is a drug development strategy in which one drug is developed for use in multiple indications.

This has been described as “the hardest strategy to pull off and the most impactful.” It is a strategy that comes with significant risk – there is a lot riding on the one drug candidate and if the drug fails in its first trial, it can spell disaster for further development. But if a company can pull it off, the strategy can maximize asset value and create a very efficient drug development business that is more about clinical execution than finding the next blockbuster. The result can be a drug which can achieve enormous patient impact and business scale.

The attractions of a pipeline-in-a-drug asset include:
Lower development costs – savings on discovery, preclinical and Phase 1 development.
Maximizing commercial potential – by pursuing multiple, discrete patient populations, the drug’s addressable market size can be maximized.
Commercialization efficiencies – there are substantial sales and marketing savings and each new approval and its market uptake is often amplified by the previous approval(s).
The pipeline-in-a-drug strategy is said to reflect the evolution of the “blockbuster” ambition. Rather than relying on a single, broadly defined indication, pharma interest turned to demonstrating the efficacy of a pathway-targeted product in a range of conditions involving the implicated pathway.

It has been predicted that the “pipeline-in-a-drug” strategy will lose its attraction to pharma under the United States’ IRA price-setting legislation. It is reasoned that pharma will now be incentivized to seek approval in the broadest possible non-orphan indication to maximize sales during the pre-price negotiating window. In the case of orphan indications, pharma may be incentivized to pursue just one indication instead of multiple, to remain exempt from IRA price-setting.

However, NNZ-2591 comes with all the attractions of a pipeline-in-a-drug asset, as listed above, but none of the disadvantages that come with IRA price-setting. As discussed here recently, drugs in the paediatric orphan indications being developed by Neuren are covered by Medicaid and private health insurance, rather than Medicaire, which is the price-setter under the IRA. NNz-2591 should therefore remain outside the reach of the IRA legislation.

NNZ-2591 - what is there not for pharma to love about this "pipeline-in-a-drug"?

https://axial.substack.com/p/drugs-that-are-their-own-pipelines

https://www.forbes.com/sites/davids...-its-a-new-blockbuster-model/?sh=dddbdbb55d13

https://www.linkedin.com/pulse/inflation-reduction-act-changes-biopharma-pipeline-bd-singh-ph-d-

Expand

”NNZ-2591 - what is there not for pharma to love about this "pipeline-in-a-drug"?”

The price they will have to pay Neuren HT!

.
NEU Price at posting: $21.64 Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

VMM

'Big tick': Viridis positions for global leadership with Colossus pre-feasibility study

HotCopper Highlights: RIP to Botanix (for now); Droneshield new ATH; Trigg mystery halt

Week 28 Wrap: Tariff chaos back for some reason; CBA holds strong

ILU

Rare earths stocks surge as Pentagon buys big stake in US REE miner

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Trump just dropped a 200% tariff bomb. Here's how to cash in

CWX

Carawine faces Fraser Range JV collapse as IGO moves to scrap partnership

AAU

Antilles brings Chinese ally on board to keep Neuva Sabana work chugging on

LIS

'Opens doors': Li-S Energy the first Oz company to produce lithium metal foils

AII

Inside the depths of Panasqueira: A legacy carved in rock

There are more pages in this discussion • 111 more messages in this thread...

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $14.57		Change -0.040(0.27%)		Mkt cap ! $1.813B

Open	High	Low	Value	Volume
$14.94	$15.19	$14.51	$8.165M	551.5K

Buyers (Bids)

No.	Vol.	Price($)
1	2735	$14.55

Sellers (Offers)

Price($)	Vol.	No.
$14.65	1396	1

View Market Depth

No.	Vol.	Price($)
2	707	14.500
1	117	14.480
1	3500	14.420
1	3472	14.400
1	40	14.250

Price($)	Vol.	No.
14.800	1000	1
14.980	7000	1
15.000	425	3
15.130	13458	1
15.180	539	2

Last trade - 16.10pm 11/07/2025 (20 minute delay)

NEU (ASX) Chart

Pipeline-in-a-drug, page-2

'Big tick': Viridis positions for global leadership with Colossus pre-feasibility study

HotCopper Highlights: RIP to Botanix (for now); Droneshield new ATH; Trigg mystery halt

Week 28 Wrap: Tariff chaos back for some reason; CBA holds strong

Rare earths stocks surge as Pentagon buys big stake in US REE miner

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Trump just dropped a 200% tariff bomb. Here's how to cash in

Carawine faces Fraser Range JV collapse as IGO moves to scrap partnership

Antilles brings Chinese ally on board to keep Neuva Sabana work chugging on

'Opens doors': Li-S Energy the first Oz company to produce lithium metal foils

Inside the depths of Panasqueira: A legacy carved in rock

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-2

Top Stories

'Big tick': Viridis positions for global leadership with Colossus pre-feasibility study

HotCopper Highlights: RIP to Botanix (for now); Droneshield new ATH; Trigg mystery halt

Week 28 Wrap: Tariff chaos back for some reason; CBA holds strong

Rare earths stocks surge as Pentagon buys big stake in US REE miner

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Trump just dropped a 200% tariff bomb. Here's how to cash in

Carawine faces Fraser Range JV collapse as IGO moves to scrap partnership

Antilles brings Chinese ally on board to keep Neuva Sabana work chugging on

'Opens doors': Li-S Energy the first Oz company to produce lithium metal foils

Inside the depths of Panasqueira: A legacy carved in rock

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News